Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
I haven't been here in a while, and I apologize if this has already been discussed. But has anyone here noticed that this fund will have a new manager in April? Does anyone know why this is coming about? I thought the recent manager had done a very good job.
Thanks for the info. Now I guess the key question is: does anyone know anything about the new manager? It appears he has been at TRP for 6 years. Nothing was said in the annual report about any experience in health care stocks.
Mike: Here's a Barron's article from a year ago that offers insight into this PM. As an owner of PRHSX, I'm confident in the abilities he brings to the portfolio. JMHO.
Mike_Martino: PRHSX is a keeper, keeper, keepper! A little background on the new manager Ziad Bakri. Regards, Ted T.Rowe Price Health Sciences' new manager will be Ziad Bakri, who on April 1 will join the fund as comanager. On July 1, Bakri, a medical doctor who has been a healthcare analyst at T. Rowe Price since 2011 and previously was a biotech analyst at Cowen and Co., will become the fund's sole manager. The firm also announced that it plans to hire additional team members on its healthcare research team, including a biotech analyst.
Comments
http://www.mutualfundobserver.com/discuss/discussion/25736/taymour-r-tamaddon-to-leave-t-rowe-price-health-sciences-fund-but-stays-with-t-rowe-price#latest
http://www.barrons.com/articles/SB50001424053111904703704579507953523415572
Regards,
Ted
T.Rowe Price Health Sciences' new manager will be Ziad Bakri, who on April 1 will join the fund as comanager. On July 1, Bakri, a medical doctor who has been a healthcare analyst at T. Rowe Price since 2011 and previously was a biotech analyst at Cowen and Co., will become the fund's sole manager. The firm also announced that it plans to hire additional team members on its healthcare research team, including a biotech analyst.